We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · January 24, 2022

Characterization of Residual Facial Dermatitis During Dupilumab Therapy

Dermatitis

 

Additional Info

Dermatitis
Characterization of Residual Facial Dermatitis during Dupilumab Therapy: A Retrospective Chart Review to Delineate the Potential Role of Expanded Series Patch Testing
Dermatitis 2021 Nov 27;33(1)51-61, AG Ashbaugh, EM Murase, J Raffi, N Botto, JE Murase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading